Lyka Labs Limited

LYKALABS

INE933A01014

Pharmaceuticals

Delayed NSE India S.E. Other stock markets 12:43:54 14/06/2024 BST			5-day change	1st Jan Change
108.6 ^INR	+0.74%		+1.54%	-12.28%

02-08	Lyka Labs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
2023	Lyka Labs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	CI

Lyka Labs Limited Receives Product Permission from the Central Drugs Standard Control Organization of India to Manufacture and Market Tofacitinib Ointment 2% w/w

October 10, 2023 at 06:41 am

Lyka Labs Limited announced that the Company has received the product permission from the Central Drugs Standard Control Organization of India to Manufacture and Market Tofacitinib Ointment 2% w/w. The Company has received this permission after successfully completing the Clinical Trial on 125 patients across 8 Clinical Trial Centers within India.

Latest news about Lyka Labs Limited

Lyka Labs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-08	CI
Lyka Labs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-02	CI
Lyka Labs Gets Indian Regulator's Nod to Market Tofacitinib Ointment	10/10/23	MT
Lyka Labs Limited Receives Product Permission from the Central Drugs Standard Control Organization of India to Manufacture and Market Tofacitinib Ointment 2% w/w	10/10/23	CI
Lyka Labs Limited Announces Cessation of Sandeep Parikh as Independent Director	27/09/23	CI
Lyka Labs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	02/08/23	CI
Lyka Labs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23/05/23	CI
Lyka Labs Limited announced that it has received INR 453.375 million in funding from Ipca Laboratories Limited	14/03/23	CI
Lyka Labs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	07/02/23	CI
Lyka Labs Limited announced that it expects to receive INR 453.375 million in funding from Ipca Laboratories Limited	20/01/23	CI
Lyka Labs Limited completed the acquisition of Animal Healthcare Business from Agilis Healthcare Pvt. Ltd. for INR 32.5 million.	31/12/22	CI
Lyka Labs to Acquire Agilis' Animal Healthcare Business	21/12/22	MT
Lyka Labs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	09/11/22	CI
Lyka Labs Limited agreed to acquire Animal Healthcare Business from Agilis Healthcare Pvt. Ltd. for INR 35 million.	08/11/22	CI

Chart Lyka Labs Limited

Duration

Period

More charts

Company Profile

Lyka Labs Limited is an India-based company that is engaged in the business of pharmaceutical and related activities, including research. The Company is focused on lyophilization - formulations/bulk sterile active pharmaceutical ingredients (APIs), and new product development including novel drug delivery systems in both topical preparation and lyophilized products. The Company manufactures pharmaceutical products, such as dry powder, liquid injections, lyophilized injections, ointment/creams and lotions, and external preparations for several international markets and the domestic market. It offers formulations, such as emollient, anti-aging, cleansing lotion, hair care products, anti-dandruff shampoo, sunscreen, anti-acne, antioxidant tablets, antioxidants combination, proton pump inhibitor, anti-fungal, anti-malarial, anti-bacterial, corticosteroid hormones and cephalosporins. The Company's subsidiaries include Lyka BDR International Limited and Lyka Exports Limited.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LYKA LABS LIMITED	-12.28%	43M
NOVO NORDISK A/S	+42.49%	630B
JOHNSON & JOHNSON	-7.15%	350B
MERCK & CO., INC.	+18.77%	328B
ABBVIE INC.	+8.79%	298B
ASTRAZENECA PLC	+18.06%	246B
ROCHE HOLDING AG	+0.65%	225B
NOVARTIS AG	+10.89%	218B
AMGEN INC.	+3.68%	160B
PFIZER, INC.	-4.38%	156B

Other Pharmaceuticals